{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE327nnn/GSE327216/"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Genomics"],"species":["Homo sapiens"],"gds_type":["Non-coding RNA profiling by array"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE327216"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"Circulating miR-22 predicts TACE response and targets WEE1 in hepatocellular carcinoma","description":"Transarterial Chemoembolization (TACE) is the standard therapy for intermediate-stage liver cancer, yet high failure rates and a lack of early biomarkers remain significant challenges. Our study shows that circulating miR-22 levels increase significantly within 48 hours in TACE non-responders, providing a much faster alternative to traditional imaging for identifying treatment failure. Mechanistically, we identified the G2/M checkpoint kinase WEE1 as a direct functional target of miR-22. The miR-22/WEE1 axis has been identified as both a reliable predictor of outcomes and a potential target for personalized therapeutic interventions.","dates":{"publication":"2026/05/06"},"accession":"GSE327216","cross_references":{"GSM":["GSM9651393","GSM9651392","GSM9651391","GSM9651390","GSM9651397","GSM9651386","GSM9651396","GSM9651395","GSM9651394","GSM9651400","GSM9651389","GSM9651399","GSM9651388","GSM9651398","GSM9651387"],"GPL":["15018"],"GSE":["327216"],"taxon":["Homo sapiens"],"PMID":["[42041589]"]}}